van der Wall SJ, Lip GYH, Teutsch C, Kalejs O, Lyrer P, Hall C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Zint K, Zhai D, Huisman MV, GLORIA-AF Investigators. Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. Eur J Intern Med. 2021 Sep;91:75-80. doi: 10.1016/j.ejim.2021.05.020
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Xie J, Juliao PC, Gilsdorf JR, Ghosh D, Patel M, Marrs CF. Identification of new genetic regions more prevalent in nontypeable haemophilus influenzae otitis media strains than in throat strains. J Clin Microbiol. 2006 Dec;44(12):4316-25. doi: 10.1128/JCM.01331-06